羟基脲加干扰素a-2b治疗慢性粒细胞白血病慢性期的疗效观察  

作　　者：廖春淑[1] 屈军[1] 薛斗[1] 何秋鸿[1] 

机构地区：[1]四川省阆中市人民医院,637400

出　　处：《当代医学》2010年第3期146-146,156,共2页Contemporary Medicine

摘　　要：目的观察羟基脲(HU)加重组人干扰素a-2b(IFNa-2b)治疗慢性粒细胞白血病(CML)慢性期的疗效,以提高CML的疗效。方法总结了25例应用HU加IFNa-2b治疗的CML慢性期,分析疗效及药物的毒副反应,并与同期应用HU治疗的21例CML慢性期病例进行比较。结果HU加IFNa-2b治疗组CHR率为96%,明显高于HU治疗的对照组,治疗组IFNa-2b主要毒副反应为畏寒、发热、头痛、肌痛及骨骼痛,经对症治疗,多数病人能耐受。结论HU加IFNa-2b是治疗CML慢性期较为有效的化疗方案。Objective To observe the healing effect of hydroxycarbamide（HU） and reforming human interferon （IFNa-2b） in treating chronic myelocytic leukemia（CML）＇stable period and to raise the healing effect of CML. Methods To summarise 25 patients of CML＇stable period treated by HU and IFNa-2b,To analyse the healing effect and drug＇s toxicity and to compaer with 21 patients of CML＇ stable period treated by HU in corrsponding time. Results The group of HU and IFNa-2b＇CHR rate is 96%, obviously higher to the control group. The toxicity of IFNa-2b in treating group are chilly, fever, headache, muscle pain, bone pain.most of patients can bearable by proper treating.Conclusion The HU and IFNa-2b is more effective chemo-treatment prposal.

关 键 词：慢性粒细胞白血病 慢性期 治疗 羟基脲 A-干扰素 

分 类 号：R733.72[医药卫生—肿瘤] R735[医药卫生—临床医学]